Piper Heartland Healthcare Capital
VC Fund
Piper Heartland Healthcare Capital is a buyout fund managed by Piper Sandler. The fund targets to invest in healthcare sector.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 5%
Last updated:
For AI agents: llms.txt
Industries Piper Heartland Healthcare Capital invests in
Stages Piper Heartland Healthcare Capital invests in
Countries Piper Heartland Healthcare Capital invests in
Investment Focus
Industry
- Biotechnology 13 (62%)
- Medical 8 (38%)
- Health Care 8 (38%)
- Therapeutics 7 (33%)
- Life Science 5 (24%)
Stage
- Series C 8 (38%)
- Series B 6 (29%)
- Series D 3 (14%)
- Venture - Series Unknown 2 (10%)
- Series A 1 (5%)
Country
- United States 12 (57%)
- United Kingdom 2 (10%)
- China 1 (5%)
- Canada 1 (5%)
- Australia 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Artios Pharma
|
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $115M / Series D / Nov 17, 2025 | |
Kardium
|
Kardium is a medical solutions company that develops a globe pulsed field system for the diagnosis and treatment of atrial fibrillation. Its flagship Globe Pulsed Field System integrates high-definition mapping, pulmonary vein isolation, and atrial ablation into a single spherical catheter featuring 122 electrodes. | $250.2M / Private Equity / Jul 02, 2025 | |
Arbor Biotechnologies
|
Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases. The company utilizes artificial intelligence and high-throughput screening to discover and optimize novel gene-editing systems. Its research focuses on expanding the CRISPR-based gene editing toolbox for therapeuticapplications. Arbor aims to develop treatments for rare and complex diseases by engineering precise and efficient genetic modifications. | $73.9M / Series C / Mar 18, 2025 | |
OrganOx
|
OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford. | $160M / Venture - Series Unknown / Feb 24, 2025 | |
Saluda Medical
|
Saluda Medical was established in 2013 with the goal of commercializing four years of research from NICTA, Australia’s information communications technology center of excellence.Our team is made up of world-class engineers, clinicians and seasoned professionals with experience in bringing medical technologies to life.Our company is founded on astrong foundation of science and we are dedicated to developing breakthrough | $100M / Venture - Series Unknown / Jan 10, 2025 | |
Maze Therapeutics
|
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.andits also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases. | $115M / Series D / Dec 03, 2024 | |
Alentis Therapeutics
|
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases. | $181.4M / Series D / Nov 12, 2024 | |
AvenCell
|
Based on our deep science and focused on patients in need. | $112M / Series B / Oct 22, 2024 | |
Endeavor BioMedicines
|
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis. The company was founded in 2018 and is based in Solana Beach, California, United States. | $132.5M / Series C / Apr 24, 2024 | |
Alumis
|
Alumis is a precision medicines company looking to eliminate the “all-comers” approach that is seen with today’s treatments for people with autoimmune disease. Even with the innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of theirdisease without life-impacting side effects. Esker leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease. | $259M / Series C / Mar 06, 2024 | |
| See all 21 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Piper Heartland Healthcare Capital invest in?
Piper Heartland Healthcare Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series C and Series B stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Piper Heartland Healthcare Capital last invest?
The most recent investment recorded for Piper Heartland Healthcare Capital closed in Nov 2025. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
